Results 151 to 160 of about 50,442 (246)

Autologous CD19-28z Chimeric Antigen Receptor-expressing T-lymphocytes [PDF]

, 2020
openaire   +1 more source

Circulating tumour cells (CTCs) in haematological malignancies: Advances in biology and clinical relevance with a focus on multiple myeloma

British Journal of Haematology, EarlyView.
Spatial heterogeneity limits the sensitivity of bone marrow biopsies, resulting in false‐negative findings. Circulating tumour cells (CTCs) provide a systemic, stratified monitoring approach, using flow cytometry for high tumour burden and EuroFlow or allele‐specific oligonucleotide PCR (ASO‐PCR) for minimal residual disease to enable early relapse ...
Chin‐Mu Hsu, Jui‐Feng Hsu, Jee‐Fu Huang, Yi‐Chang Liu   +3 more
wiley   +1 more source

Heterogeneous Activated B Cell Compartments Arising Early and Transiently After SARS-CoV-2 Vaccination. [PDF]

Eur J Immunol
Fernandez Blanco L, Kuijper LH, Kummer LYL, Verstegen NJM, Bos A, Claireaux M, Duurland MC, Jorritsma T, Steenhuis M, Kerster G, Vallejo JJG, van Gils MJ, van Dam KPJ, Stalman EW, Wieske L, Boekel L, Wolbink GJ, Tas SW, Rispens T, Kuijpers TW, Eftimov F, Brinke AT, van Ham SM, of T2B! Immunity Against SARS‐CoV‐2 Study Group.   +23 more
europepmc   +1 more source

CAR-T therapy for autoimmune rheumatic diseases: navigating clinical frontiers between breakthroughs and uncertainties. [PDF]

Clin Exp Med
Cheng J, Zhang X, Fan Y, Zhang Z.
europepmc   +1 more source

Tafasitamab as Monotherapy or in Combination in Japanese Patients With B‐Cell Non‐Hodgkin Lymphoma: Results From the Phase 1b J‐MIND Study

Cancer Science, EarlyView.
J‐MIND evaluated the safety and tolerability of tafasitamab, a CD19‐targeting monoclonal antibody, alone or in combination with other therapies in Japanese patients with B‐cell non‐Hodgkin lymphoma (NHL). Most common treatment‐emergent adverse events across all groups were hematological, and no serious tafasitamab treatment‐related or fatal adverse ...
Koji Izutsu, Noriko Fukuhara, Junichiro Yuda, Youko Suehiro, Shigeru Kusumoto, Marie‐Laure Casadebaig, Kazumi Suzukawa, Kentaro Fukushima   +7 more
wiley   +1 more source

Chimeric Antigen Receptor T-Cell Therapy: More Than an Anti-Cancer Drug. [PDF]

HLA
Schenk HCM, Gille I, Arana C, Rovira J, Palou E, Diekmann F, Roelen DL, Heemskerk MHM, Heidt S.   +8 more
europepmc   +1 more source

Diverging in Vivo Immune Response Patterns After Oral Food Challenge in Peanut Allergic Adults

Clinical &Experimental Allergy, EarlyView.
After the oral food challenge, peanut (PN)‐allergic adults were monitored over 4 weeks, which revealed diverging immune response patterns, with strong responders (SR) exhibiting heightened Ara h 2+ B cell expansion, PN sIgE induction and increasing PN‐specific Tconv. Weak responders (WR) had more activated PN‐specific Tregs.
Florent Fauchère, Aikaterina Alexiou, Veronika Höfer, Kirsten Beyer, Sabine Dölle‐Bierke, Andreas Thiel, Margitta Worm, Julian Braun   +7 more
wiley   +1 more source

Advances in chimeric antigen receptor-natural killer cell therapy: from mechanisms and preclinical studies to clinical application. [PDF]

Front Oncol
Ren T, Wang F, Liu X, Guo J, Xie S.
europepmc   +1 more source

Ethical and Regulatory Considerations in the Clinical Translation of Pluripotent Stem Cell‐Derived NK Cell Therapies

Cell Proliferation, EarlyView.
Advancements in the generation of human pluripotent stem cell‐derived natural killer (PSC‐NK) cells have attracted considerable attention within the biomedical research community, offering a promising off‐the‐shelf technique for universal immune therapy.
Qianwen Chen, Jianwei Lv, Xinwei Xie, Hanlin Zhu, Zhenyu Xiao, Yaojin Peng   +5 more
wiley   +1 more source

Successful fresh formulation CD19 CAR-T cell therapy for GAD65 antibody-mediated cerebellar ataxia. A Case Report. [PDF]

Front Immunol
Vaisvilas M, Cernauskiene S, Petrosian D, Giedraitiene N, Stoskus M, Griskevicius L.   +5 more
europepmc   +1 more source